Webcast ImageWebcast
STRIVE Part A Phase 2 Topline Results (Replay)
03/19/18 at 8:00 a.m. ET
STRIVE Part A Phase 2 Topline Results
Monday, March 19, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through late stage clinical trials, and developing its antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Cidara is developing its antibody-drug conjugates as part of its novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.


Download Documentation Corporate Presentation March 2018

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
03/22/18 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $5.40 with a 52 week high of $8.80 and a 52 week low of $5.30.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources